Baystreet.ca – Stocks In Play

5/19/2025 – 11:13 AM EST – GT Biopharma, Inc. : Announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. GT Biopharma’s second-generation TriKE, GTB-3650, is currently being evaluated in a Phase 1 dose escalation trial for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. Cohort 1 has been successfully completed with patients having undergone the first and second dosing cycles. Following the formal safety review, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2, with the first patient now having been treated with the first dose cycle. GT Biopharma, Inc.
shares N.GTBP are trading up 25 cents at $2.48.

Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=GTBP&qmodStoryID=7563340344895246